These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24928889)

  • 1. Extending an in vitro panel for estrogenicity testing: the added value of bioassays for measuring antiandrogenic activities and effects on steroidogenesis.
    Wang S; Rijk JC; Besselink HT; Houtman R; Peijnenburg AA; Brouwer A; Rietjens IM; Bovee TF
    Toxicol Sci; 2014 Sep; 141(1):78-89. PubMed ID: 24928889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 155-plex high-throughput in vitro coregulator binding assay for (anti-)estrogenicity testing evaluated with 23 reference compounds.
    Wang S; Houtman R; Melchers D; Aarts J; Peijnenburg A; van Beuningen R; Rietjens I; Bovee TF
    ALTEX; 2013; 30(2):145-57. PubMed ID: 23665804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust array-based coregulator binding assay predicting ERα-agonist potency and generating binding profiles reflecting ligand structure.
    Aarts JM; Wang S; Houtman R; van Beuningen RM; Westerink WM; Van De Waart BJ; Rietjens IM; Bovee TF
    Chem Res Toxicol; 2013 Mar; 26(3):336-46. PubMed ID: 23383871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards an integrated in vitro strategy for estrogenicity testing.
    Wang S; Aarts JM; de Haan LH; Argyriou D; Peijnenburg AA; Rietjens IM; Bovee TF
    J Appl Toxicol; 2014 Sep; 34(9):1031-40. PubMed ID: 24114741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization and prevalidation of the in vitro ERalpha CALUX method to test estrogenic and antiestrogenic activity of compounds.
    van der Burg B; Winter R; Weimer M; Berckmans P; Suzuki G; Gijsbers L; Jonas A; van der Linden S; Witters H; Aarts J; Legler J; Kopp-Schneider A; Bremer S
    Reprod Toxicol; 2010 Aug; 30(1):73-80. PubMed ID: 20435135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays.
    Sonneveld E; Jansen HJ; Riteco JA; Brouwer A; van der Burg B
    Toxicol Sci; 2005 Jan; 83(1):136-48. PubMed ID: 15483189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of in vitro and in vivo screening models for androgenic and estrogenic activities.
    Sonneveld E; Riteco JA; Jansen HJ; Pieterse B; Brouwer A; Schoonen WG; van der Burg B
    Toxicol Sci; 2006 Jan; 89(1):173-87. PubMed ID: 16221957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coupling the H295R with ERα and AR U2OS CALUX assays enables simultaneous testing for estrogenic, anti-androgenic and steroidogenic modalities.
    Nikopaschou MS; Félix A; Mollergues J; Scholz G; Schilter B; Marin-Kuan M; Fussell KC
    Toxicol Sci; 2023 Jul; 194(2):191-208. PubMed ID: 37261848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches.
    Zhang L; Sedykh A; Tripathi A; Zhu H; Afantitis A; Mouchlis VD; Melagraki G; Rusyn I; Tropsha A
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):67-76. PubMed ID: 23707773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of estrogen and androgen activity of food contact materials by different in vitro bioassays (YES, YAS, ERα and AR CALUX) and chromatographic analysis (GC-MS, HPLC-MS).
    Mertl J; Kirchnawy C; Osorio V; Grininger A; Richter A; Bergmair J; Pyerin M; Washüttl M; Tacker M
    PLoS One; 2014; 9(7):e100952. PubMed ID: 25000404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A testing strategy for the identification of mammalian, systemic endocrine disruptors with particular focus on steroids.
    Kolle SN; Ramirez T; Kamp HG; Buesen R; Flick B; Strauss V; van Ravenzwaay B
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):259-78. PubMed ID: 22554500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Throughput Analysis of Endocrine-Disrupting Compounds Using BLYES and BLYAS Bioluminescent Yeast Bioassays.
    Xu T; Young A; Narula J; Sayler G; Ripp S
    Methods Mol Biol; 2020; 2081():29-41. PubMed ID: 31721116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization and prevalidation of the in vitro AR CALUX method to test androgenic and antiandrogenic activity of compounds.
    van der Burg B; Winter R; Man HY; Vangenechten C; Berckmans P; Weimer M; Witters H; van der Linden S
    Reprod Toxicol; 2010 Aug; 30(1):18-24. PubMed ID: 20438827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The assessment of estrogenic or anti-estrogenic activity of chemicals by the human stably transfected estrogen sensitive MELN cell line: results of test performance and transferability.
    Witters H; Freyberger A; Smits K; Vangenechten C; Lofink W; Weimer M; Bremer S; Ahr PH; Berckmans P
    Reprod Toxicol; 2010 Aug; 30(1):60-72. PubMed ID: 20362049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of putative steroid receptor antagonists in bottled water: combining bioassays and high-resolution mass spectrometry.
    Wagner M; Schlüsener MP; Ternes TA; Oehlmann J
    PLoS One; 2013; 8(8):e72472. PubMed ID: 24015248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of metabolic enzymes to improve predictivity of reporter gene assay results for estrogenic and anti-androgenic activity.
    van Vugt-Lussenburg BMA; van der Lee RB; Man HY; Middelhof I; Brouwer A; Besselink H; van der Burg B
    Reprod Toxicol; 2018 Jan; 75():40-48. PubMed ID: 29162470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-mediated estrogenicity of native and chemically dispersed crude oil determined using adapted microscale reporter gene assays.
    Johann S; Esser M; Nüßer L; Altin D; Hollert H; Seiler TB
    Environ Int; 2020 Jan; 134():105320. PubMed ID: 31739133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic depsipeptide mycotoxin exposure may cause human endocrine disruption: Evidence from OECD in vitro stably transfected transcriptional activation assays.
    Park Y; Lee HS
    Reprod Toxicol; 2021 Mar; 100():52-59. PubMed ID: 33346041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the results of in vitro receptor binding assay to human estrogen receptor alpha and in vivo uterotrophic assay: comparative study with 65 selected chemicals.
    Akahori Y; Nakai M; Yamasaki K; Takatsuki M; Shimohigashi Y; Ohtaki M
    Toxicol In Vitro; 2008 Feb; 22(1):225-31. PubMed ID: 17904329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
    LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.